Immuno-Oncology Drugs Market Forecast 2026: Market Size, Competitive Landscape And Growth Drivers
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Immuno-Oncology Drugs Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The immuno-oncology drugs market size has experienced rapid growth in recent years. It is anticipated to increase from $120.37 billion in 2025 to $136.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.1%. This historical expansion can be ascribed to several factors, including the initial limited availability of immuno-oncology drugs, a reliance on conventional chemotherapy, the rising prevalence of cancers such as melanoma and lung cancer, expanding oncology-focused research initiatives, and early regulatory approvals granted for monoclonal antibodies.
The immuno-oncology drugs market size is anticipated to experience substantial growth in the coming years. It will grow to $226.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. This growth throughout the forecast period can be attributed to advancements such as the development of bispecific antibodies and oncolytic virus therapies, the expansion of personalized immunotherapy solutions, increasing investment in adoptive cell transfer therapies, rising healthcare expenditure on cancer treatment, and the integration of digital platforms for patient monitoring and clinical trials. Furthermore, major trends in the forecast period encompass the rising adoption of immune checkpoint inhibitors across multiple cancer types, increased development of cancer vaccines and adoptive cell therapies, a growing focus on personalized immuno-oncology treatments, the expansion of hospital and ambulatory surgical center-based immunotherapy programs, and rising clinical trials and research activities involving monoclonal antibodies.
Get A Free Sample Report With In-Depth Market Insights:
Immuno-Oncology Drugs Market Growth Backed By Core Demand Fundamentals
The rising occurrence of cancer cases is anticipated to spur expansion within the immuno-oncology drugs market in the coming years. Cancer is characterized by the uncontrolled proliferation of anomalous cells, which can potentially disseminate throughout the body and disrupt normal physiological functions. The rise in cancer diagnoses stems from elements like an aging global demographic, evolving lifestyle habits, and advancements in detection techniques. Immuno-oncology drugs address this challenge by activating the body’s own immune defenses to identify and eradicate cancerous cells, thereby offering more potent and targeted therapeutic avenues. For example, in 2023, Cancer Australia, an Australia-based government agency, reported approximately 164,694 new cancer cases diagnosed and 51,269 deaths. The most prevalent forms were prostate, breast, melanoma, colorectal, and lung cancers, whereas rare cancers represented about one-third of diagnoses and 42% of fatalities. Consequently, the growing frequency of cancer cases is a significant catalyst for the immuno-oncology drugs market.
Immuno-Oncology Drugs Market Segments: Where Is Growth Concentrated?
The immuno-oncology drugs market covered in this report is segmented –
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies
Immuno-Oncology Drugs Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the immuno-oncology drugs market are entering collaborations to create and bring to market a novel checkpoint antibody, aiming to boost the effectiveness of cancer treatments. These strategic alliances promote innovation through the exchange of knowledge across various disciplines, which contributes to the quicker development of combination therapies, customized treatments, and advanced drug delivery systems. For instance, in March 2023, BioNTech SE, a Germany-based company, formed a partnership with OncoC4 Inc, a US-based pharmaceutical company, to jointly develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate known as ONC-392. The objective of this partnership is to improve cancer treatment options across numerous solid tumor indications.
Immuno-Oncology Drugs Market Key Participants And Competitive Landscape
Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.
View The Full Immuno-Oncology Drugs Market Report:
Immuno-Oncology Drugs Market Largest Region By Revenue And Market Share
North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
